Bain Capital, Advent International and EQT AB are among the private equity firms competing to acquire Japanese cybersecurity ...

Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the appointment ...

OpenStudio is a commerce app that connects consumers with skilled artisans and craftspeople, while Wasabi brings family and ...

The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.

Funding was led by New Enterprise Associates, with participation from Foresite Capital and multiple other investors.

Teskey noted that Brookfield's latest flagship rounds, including the Global Transition Fund and Real Estate flagship fund, are slated for final close in the first half of 2025. Complementary ...

Palantir produced $2.8 billion in revenues in 2024, far and above BBAI’s $165 million. While that’s not a dealbreaker, ...

Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced the ...

More formally known as Alexandre L’Heureux, he has helped transform a small Montreal-based engineering company once known as Genivar Inc. into a multinational giant called WSP Global Inc. Since he ...

Abcuro Inc. has raised a $200 million Series C financing to fund late-stage development and support commercial launch ...

Fundraising in the private-markets business can be tough. Wining and dining big investors for each new vehicle creates an endless treadmill. Worse, the typical closed-end fund structure ignores ...

Rising health insurance exhange enrollment, paired with stricter Medicare marketing rules, attracted rogue actors to the ...